Eugeni Bruguera Cortada

Institutions of which they are part

Senior researcher
Psychiatry, Mental Health and Addictions

Vall Hebron Institut de Recerca

Eugeni Bruguera Cortada

Institutions of which they are part

Senior researcher
Psychiatry, Mental Health and Addictions

Vall Hebron Institut de Recerca

Projects

An effectiveness and safety study of varenicline for smoking cessation in hospitalized patients with psychiatric disorders

IP: Eugeni Bruguera Cortada
Collaborators: -
Funding agency: Pfizer Inc
Funding: 90196.52
Reference: VARENICLINE_WI231379-PFIZER2017
Duration: 29/01/2018 - 01/04/2020

Related news

Members of the Psychiatry, Mental Health and Addictions research group at VHIR

A transdiagnostic approach drives new therapies in psychiatry for various disorders

A large-scale study involving Vall d’Hebron confirms the genetic relatedness among 14 different psychiatric disorders and groups them into five new families, paving the way for new treatments targeting their shared underlying genetic causes

The Vall d'Hebron Accredited Institute raises more than €8M in the ISCIII's AES 2025 calls

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Equip de Vall d'Hebron que ha liderat l'estudi

Vall d’Hebron finds shared genetic factors in addictions and educational attainment

The study, conducted with more than 1,400 people with addictive disorders, delves into the biological mechanisms that connect mental health, life trajectory and educational opportunities.